Browse by author
Lookup NU author(s): Professor Moein MoghimiORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020 Elsevier B.V. Considering the multifaceted protective and homeostatic roles of the complement system, many consequences arise when drug carriers, and particulate pharmaceutical formulations clash with complement proteins, and trigger complement cascade. Complement activation may induce formulation destabilization, promote opsonization, and affect biological and therapeutic performance of pharmaceutical nano- and micro-particles. In some cases, complement activation is beneficial, where complement may play a role in prophylactic protection, whereas uncontrolled complement activation is deleterious, and contributes to disease progression. Accordingly, design initiatives with particulate medicines should consider complement activation properties of the end formulation within the context of administration route, dosing, systems biology, and therapeutic perspective. Here we examine current progress in mechanistic processes underlying complement activation by pre-clinical and clinical particles, identify opportunities and challenges ahead, and suggest future directions in nanomedicine-complement interface research.
Author(s): Moghimi SM, Simberg D, Papini E, Farhangrazi ZS
Publication type: Review
Publication status: Published
Journal: Advanced Drug Delivery Reviews
Year: 2020
Volume: 157
Pages: 83-95
Online publication date: 07/05/2020
Acceptance date: 30/04/2020
ISSN (print): 0169-409X
ISSN (electronic): 1872-8294
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.addr.2020.04.012
DOI: 10.1016/j.addr.2020.04.012
PubMed id: 32389761
